Bank of America has re rated DNA and OSIP on the back of better than expected sales of NSCLC drug Tarceva . DNA has been given a target of $62 up a further 5Billion and OSIP target is $86 up about 2Billion market cap
Solbecs drug is shaping up as very (more?)effective against NSCLC .
www.forbes.com/markets/2005/04/12/0412automarketscan13.html?partner=yahoo&referrer=
- Forums
- ASX - By Stock
- tarceva
SBP
solbec pharmaceuticals limited
Bank of America has re rated DNA and OSIP on the back of better...
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
NRZ
NEURIZER LTD
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online